Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4212 | Veru-111 Wiki | 1.00 |
| drug4210 | Verapamil Wiki | 1.00 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D013577 | Syndrome NIH | 0.09 |
| D012127 | Respiratory Distress Syndrome, Newborn NIH | 0.08 |
| D055371 | Acute Lung Injury NIH | 0.08 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There is one clinical trial.
There is an urgent need for effective therapies against the novel COVID-19 virus. Studies have shown that amiodarone and verapamil can interfere with coronavirus entry and amplification by blocking ion channels. ReCOVery-SIRIO is a randomized study to investigate amiodarone or verapamil compared with usual care in symptomatic patients hospitalized with confirmed COVID-19 infection.
Description: Time to first occurrence of clinical improvement assessed on a seven category scale ranging from 1 to 7
Measure: Clinical improvement Time: Randomization to day 15Description: Time to first occurrence of clinical improvement assessed on a seven category scale ranging from 1 to 7
Measure: Clinical improvement Time: Randomization to day 7 and 28Description: assessed on a seven category scale ranging from 1 to 7
Measure: Mean change in the 7-point ordinal scale Time: Randomization to day 7,15 and 28Description: Individual endpoint
Measure: Mortality Time: Randomization to day 28Description: Defined as body temperature (≤36.6°C [axilla], or ≤37.2 °C [oral], or ≤37.8°C [rectal]) for at least 48 hours without antipyretics or until discharge, whichever is sooner.
Measure: Time to resolution of fever Time: Randomization to day 28Description: Composite endpoint
Measure: Clinical improvement or fever resolution Time: Randomization to day 7,15 and 28Description: defined as atrial fibrillation, supraventricular or ventricular tachycardia requiring treatment
Measure: Tachyarrhythmias Time: Randomization to day 28Description: Composite endpoint
Measure: Mortality or tachyarrhythmias Time: Randomization to day 28Description: Clinical improvement assessed on a seven category scale ranging from 1 to 7.
Measure: Time to clinical improvement from admission using the 7-point ordinal scale Time: Randomization to day 28Description: The National Early Warning Score (NEWS2) score. A Higher score is worse.
Measure: Change in NEWS2 score Time: Randomization to day 7 and 15Description: oxygenation index defined as quotient of partial pressure of oxygen in arterial blood (PaO2, in mmHg) and fraction of inspired oxygen (FiO2)
Measure: PO2/FIO2 Time: Randomization to day 7 and 15Description: Assessed on a modified seven category scale ranging from 1 to 7
Measure: Clinical improvement Time: Randomization to day 15Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports